A Phase 1 open-label, 4-period crossover study of safety, tolerability, and pharmacokinetic profile of intravenous-to-subcutaneous bridging study of PCN-101
Latest Information Update: 17 Aug 2023
Price :
$35 *
At a glance
- Drugs Arketamine (Primary) ; Arketamine (Primary)
- Indications Depressive disorders
- Focus Adverse reactions; Pharmacokinetics
- Sponsors ATAI Life Sciences
- 10 Aug 2023 Status changed from active, no longer recruiting to completed, according to ATAI Life Sciences Media Release.
- 08 Aug 2023 Status changed from recruiting to active, no longer recruiting, according to an Atai media release.
- 08 Aug 2023 Results presented in an ATAI Life Sciences Media Release.